Comment on “Pneumocystis jirovecii Pneumonia in Patients Treated for Solid Organ Malignancy”

TO THE EDITOR

We recently came across the case series published in the Ochsner Journal by Jackson and colleagues,¹ and the paper really struck a chord with us. This work shines a light on a critical clinical challenge that we think deserves a lot more attention—the management of Pneumocystis jirovecii pneumonia (PJP) in patients receiving dose-dense chemotherapy for solid organ malignancies.

As the authors point out, using these intense chemotherapy regimens, such as doxorubicin and cyclophosphamide, has become standard practice for treating early-stage breast cancer. But the downside is that dose-dense chemotherapy seems to be considerably increasing the risk of opportunistic infections such as PJP in these vulnerable patients. And based on the 2 case reports presented by Jackson et al, the consequences can be critical.

The mechanical ventilation and intensive supportive care that these patients required really drives home just how serious PJP can be in this context. Even more concerning is the authors' observation that clear guidelines on PJP prophylaxis are lacking. Current recommendations suggest prophylaxis for groups with a risk >3.5%,² but the 0.6% incidence rate reported by Waks et al suggests that the >3.5% threshold may not be appropriate.³

In our view, the existing evidence^3-6 calls for us to take a hard look at the current guidelines and become much more proactive about PJP prevention in patients on dose-dense chemotherapy. Here are 3 issues we need to focus on: